<qa>  What was the primary outcome of the primary treatment?Patients with moderate-to-severe psoriasis were randomly assigned to treatment for 16 weeks with either cyclosporine A 20 patients; male 200 mgday, female 150 mgday or methotrexate 20 patients; initial dose with 10 mgweek, increased up to 15 mgweek. The primary outcome was to compare the difference between the conventional subjective Psoriasis Area and Severity Index PASI and the objective PASI by using Colorimeter at 2, 4, 8, 12, and 16 weeks of treatment. The secondary outcome was differences between cyclosporine and methotrexate for treatment of psoriasis, evaluating clinical efficacy and side effects. 